Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SARS-CoV-2 beta S protein + CpG7909
- Development stage
- Unknown
- Lead developer
- Shanghai Zerun Biotechnology
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
A combination vaccine formulation consisting of **recombinant SARS-CoV-2 beta (B.1.351 variant) spike (S) protein** as the antigen and **CpG7909** (a TLR9 agonist class B CpG oligodeoxynucleotide) as an **adjuvant**. The spike protein acts as the immunogen, eliciting neutralizing antibody and cellular immune responses specifically targeting the beta variant. CpG7909 enhances immunogenicity by stimulating plasmacytoid dendritic cells and B cells via Toll-like receptor 9, promoting Th1-type responses and cytotoxic T lymphocyte activation, and boosting the breadth and magnitude of vaccine-induced immunity. This combination is under investigation primarily as a booster or primary vaccine against COVID-19, especially targeting SARS-CoV-2 variants, aiming for enhanced, durable, and broad-spectrum immune protection[2][4][6][8][9].
- Other names
- SARS-CoV-2 beta spike protein plus CpG7909SARS-CoV2 beta spike protein plus CpG7909SARS-CoV 2 beta spike protein plus CpG7909SARS-CoV-2 beta S protein with CpG7909SARS-CoV2 beta S protein with CpG7909SARS-CoV 2 beta S protein with CpG7909
02
Targets
SARS-CoV-2 spikeTLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on SARS-CoV-2 beta S protein + CpG7909.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS-CoV-2 beta S protein + CpG7909.